Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

Our rapid and easy-to-use tests incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as cystic fibrosis and COPD. 

 

 

NEATstik-LFDELISAkit

CLINICAL RESEARCH SERVICES
ACTIVITY PROFILING
TARGET VALIDATION
CLINICAL TRIAL SUPPORT 

CLINICAL/POINT OF CARE TESTS
ProteaseTags®
CROSS PLATFORM TECHNOLOGY

ProteaseTag® Immunoassays
KIT SALES
SERVICE PROVISION
DRUG DISCOVERY

SMART MOLECULE DESIGN
ProteaseTags® LIBRARY
INHIBITOR/KINETIC ANALYSIS
CUSTOM DESIGN & SYNTHESIS

 

News

ProAxsis CEO to present at Biotech in Europe
Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in ...
ProAxsis builds market presence
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland...
ProAxsis’ ProteaseTag® technology highlighted at ECFC 2016
ProAxsis (www.proaxsis.com) presented data for the first time on its active Cathepsin G (CatG) Immunoas...
ProAxsis team to attend BIO 2016
ProAxsis will be attending the BIO 2016 conference, taking place at the Moscone Convention Center in ...
Proaxsis